Background: Galectin-1 (Gal-1) plays major roles in cancer by modulating different processes leading to tumor development and progression. In the last years, it has been suggested as a promising target for anticancer therapy. Recently, aflibercept has shown high affinity for Gal-1. Here, we investigated how aflibercept could exert its antitumor activity via Gal-1-driven pathways in neuroendocrine carcinomas (NECs). Methods and Results: NEC tumor xenografts were used to assess the effect of aflibercept on Gal-1 functions. Aflibercept induced a significant reduction of Gal-1 at epithelial, stromal, and extracellular localizations in lung NEC, whereas this was not observed in colon NECs, which displayed low expression of Gal-1. Additionally, aflibercept significantly reduced p-VEGFR2 protein, extracellular matrix remodeling, epithelial-mesenchymal transition, and activation of cancer-associated fibroblast hampering cell invasion in lung NEC but not in colon NEC. Gal-1 screening in human NECs confirmed that pulmonary and pancreatic tumors displayed higher levels of Gal-1 than colon NECs, becoming good candidates to benefit from aflibercept treatment. Conclusions: The lack of validated predictive markers of aflibercept is a weakness for guaranteeing the best treatment management with this drug. This work provides new mechanistic insight of aflibercept depending on Gal-1. Thus, in tumors overexpressing Gal-1, aflibercept has not only an antiangiogenic effect but also prevents Gal-1-mediated tumor-stroma cross talk. The stronger aflibercept effect in tumors with high levels of Gal-1 points out this protein as a molecular marker to predict the efficacy of this agent not only for NECs but also for other tumors with high levels of this protein.

1.
Barondes
SH
,
Castronovo
V
,
Cooper
DN
,
Cummings
RD
,
Drickamer
K
,
Feizi
T
, et al
Galectins: a family of animal beta-galactoside-binding lectins
.
Cell
.
1994
Feb
;
76
(
4
):
597
8
.
[PubMed]
0092-8674
2.
van Beijnum
JR
,
Thijssen
VL
,
Läppchen
T
,
Wong
TJ
,
Verel
I
,
Engbersen
M
, et al
A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies
.
Int J Cancer
.
2016
Aug
;
139
(
4
):
824
35
.
[PubMed]
0020-7136
3.
Yang
RY
,
Rabinovich
GA
,
Liu
FT
.
Galectins: structure, function and therapeutic potential
.
Expert Rev Mol Med
.
2008
Jun
;
10
:
e17
.
[PubMed]
1462-3994
4.
Camby
I
,
Le Mercier
M
,
Lefranc
F
,
Kiss
R
.
Galectin-1: a small protein with major functions
.
Glycobiology
.
2006
Nov
;
16
(
11
):
137R
57R
.
[PubMed]
0959-6658
5.
Seelenmeyer
C
,
Wegehingel
S
,
Tews
I
,
Künzler
M
,
Aebi
M
,
Nickel
W
.
Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1
.
J Cell Biol
.
2005
Oct
;
171
(
2
):
373
81
.
[PubMed]
0021-9525
6.
Ito
K
,
Stannard
K
,
Gabutero
E
,
Clark
AM
,
Neo
SY
,
Onturk
S
, et al
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
.
Cancer Metastasis Rev
.
2012
Dec
;
31
(
3-4
):
763
78
.
[PubMed]
0167-7659
7.
Waltl
I
,
Zehetner
C
,
Seifarth
C
,
Handle
F
,
Kieselbach
GF
,
Angermann
R
, et al
Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy
.
Curr Eye Res
.
2018
Mar
;
43
(
3
):
368
75
.
[PubMed]
0271-3683
8.
Kanda
A
,
Noda
K
,
Saito
W
,
Ishida
S
.
Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy
.
Sci Rep
.
2015
Dec
;
5
(
1
):
17946
.
[PubMed]
2045-2322
9.
Dasari
A
,
Mehta
K
,
Byers
LA
,
Sorbye
H
,
Yao
JC
.
Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases
.
Cancer
.
2017
Dec
.
[PubMed]
0008-543X
10.
Sorbye
H
,
Welin
S
,
Langer
SW
,
Vestermark
LW
,
Holt
N
,
Osterlund
P
, et al
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
.
Ann Oncol
.
2013
Jan
;
24
(
1
):
152
60
.
[PubMed]
0923-7534
11.
Hainsworth
JD
,
Spigel
DR
,
Litchy
S
,
Greco
FA
.
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study
.
J Clin Oncol
.
2006
Aug
;
24
(
22
):
3548
54
.
[PubMed]
0732-183X
12.
Rodriguez-Remirez
M
,
Del Puerto-Nevado
L
,
Fernández Aceñero
MJ
,
Ebrahimi-Nik
H
,
Cruz-Ramos
M
,
Garcia-Garcia
L
, et al
Strong antitumor activity of bevacizumab and aflibercept in Neuroendocrine Carcinomas: in-depth preclinical study
.
Neuroendocrinology
.
2019
Apr
.
[PubMed]
0028-3835
13.
Hsieh
SH
,
Ying
NW
,
Wu
MH
,
Chiang
WF
,
Hsu
CL
,
Wong
TY
, et al
Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells
.
Oncogene
.
2008
Jun
;
27
(
26
):
3746
53
.
[PubMed]
0950-9232
14.
Yun
SP
,
Lee
SJ
,
Jung
YH
,
Han
HJ
.
Galectin-1 stimulates motility of human umbilical cord blood-derived mesenchymal stem cells by downregulation of smad2/3-dependent collagen 3/5 and upregulation of NF-κB-dependent fibronectin/laminin 5 expression
.
Cell Death Dis
.
2014
Feb
;
5
(
2
):
e1049
.
[PubMed]
2041-4889
15.
Zeisberg
M
,
Neilson
EG
.
Biomarkers for epithelial-mesenchymal transitions
.
J Clin Invest
.
2009
Jun
;
119
(
6
):
1429
37
.
[PubMed]
0021-9738
16.
Dvořánková
B
,
Szabo
P
,
Lacina
L
,
Gal
P
,
Uhrova
J
,
Zima
T
, et al
Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair
.
Cells Tissues Organs
.
2011
;
194
(
6
):
469
80
.
[PubMed]
1422-6405
17.
Chong
Y
,
Tang
D
,
Xiong
Q
,
Jiang
X
,
Xu
C
,
Huang
Y
, et al
Galectin-1 from cancer-associated fibroblasts induces epithelial-mesenchymal transition through β1 integrin-mediated upregulation of Gli1 in gastric cancer
.
J Exp Clin Cancer Res
.
2016
Nov
;
35
(
1
):
175
.
[PubMed]
0392-9078
18.
Wanami
LS
,
Chen
HY
,
Peiró
S
,
García de Herreros
A
,
Bachelder
RE
.
Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression
.
Exp Cell Res
.
2008
Aug
;
314
(
13
):
2448
53
.
[PubMed]
0014-4827
19.
Garcia-Carbonero
R
,
Sorbye
H
,
Baudin
E
,
Raymond
E
,
Wiedenmann
B
,
Niederle
B
, et al;
Vienna Consensus Conference participants
.
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
.
Neuroendocrinology
.
2016
;
103
(
2
):
186
94
.
[PubMed]
0028-3835
20.
Sun
JM
,
Ahn
MJ
,
Ahn
JS
,
Um
SW
,
Kim
H
,
Kim
HK
, et al
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Lung Cancer
.
2012
Aug
;
77
(
2
):
365
70
.
[PubMed]
0169-5002
21.
Cousin
JM
,
Cloninger
MJ
.
The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1
.
Int J Mol Sci
.
2016
Sep
;
17
(
9
):
E1566
.
[PubMed]
1661-6596
22.
Liu
FT
,
Rabinovich
GA
.
Galectins as modulators of tumour progression
.
Nat Rev Cancer
.
2005
Jan
;
5
(
1
):
29
41
.
[PubMed]
1474-175X
23.
Rubinstein
N
,
Alvarez
M
,
Zwirner
NW
,
Toscano
MA
,
Ilarregui
JM
,
Bravo
A
, et al
Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege
.
Cancer Cell
.
2004
Mar
;
5
(
3
):
241
51
.
[PubMed]
1535-6108
24.
Thijssen
VL
,
Hulsmans
S
,
Griffioen
AW
.
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells
.
Am J Pathol
.
2008
Feb
;
172
(
2
):
545
53
.
[PubMed]
0002-9440
25.
Usami
Y
,
Satake
S
,
Nakayama
F
,
Matsumoto
M
,
Ohnuma
K
,
Komori
T
, et al
Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression
.
J Pathol
.
2008
Jul
;
215
(
3
):
330
9
.
[PubMed]
0022-3417
26.
Vergara
D
,
Merlot
B
,
Lucot
JP
,
Collinet
P
,
Vinatier
D
,
Fournier
I
, et al
Epithelial-mesenchymal transition in ovarian cancer
.
Cancer Lett
.
2010
May
;
291
(
1
):
59
66
.
[PubMed]
0304-3835
27.
Trimboli
AJ
,
Fukino
K
,
de Bruin
A
,
Wei
G
,
Shen
L
,
Tanner
SM
, et al
Direct evidence for epithelial-mesenchymal transitions in breast cancer
.
Cancer Res
.
2008
Feb
;
68
(
3
):
937
45
.
[PubMed]
0008-5472
28.
Galván
JA
,
Astudillo
A
,
Vallina
A
,
Crespo
G
,
Folgueras
MV
,
González
MV
.
Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors
.
BMC Cancer
.
2014
Nov
;
14
(
1
):
855
.
[PubMed]
1471-2407
29.
Galván
JA
,
Astudillo
A
,
Vallina
A
,
Fonseca
PJ
,
Gómez-Izquierdo
L
,
García-Carbonero
R
, et al
Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors
.
Am J Clin Pathol
.
2013
Jul
;
140
(
1
):
61
72
.
[PubMed]
0002-9173
30.
Bacigalupo
ML
,
Manzi
M
,
Espelt
MV
,
Gentilini
LD
,
Compagno
D
,
Laderach
DJ
, et al
Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells
.
J Cell Physiol
.
2015
Jun
;
230
(
6
):
1298
309
.
[PubMed]
0021-9541
31.
Zhi
K
,
Shen
X
,
Zhang
H
,
Bi
J
.
Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers
.
J Exp Clin Cancer Res
.
2010
Jun
;
29
(
1
):
66
.
[PubMed]
0392-9078
32.
Wu
MH
,
Hong
HC
,
Hong
TM
,
Chiang
WF
,
Jin
YT
,
Chen
YL
.
Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression
.
Clin Cancer Res
.
2011
Mar
;
17
(
6
):
1306
16
.
[PubMed]
1078-0432
33.
Tang
D
,
Gao
J
,
Wang
S
,
Ye
N
,
Chong
Y
,
Huang
Y
, et al
Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
.
Tumour Biol
.
2016
Feb
;
37
(
2
):
1889
99
.
[PubMed]
1010-4283
34.
Zheng
L
,
Xu
C
,
Guan
Z
,
Su
X
,
Xu
Z
,
Cao
J
, et al
Galectin-1 mediates TGF-β-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer
.
Am J Transl Res
.
2016
Apr
;
8
(
4
):
1641
58
.
[PubMed]
1943-8141
35.
Herrera
A
,
Herrera
M
,
Guerra-Perez
N
,
Galindo-Pumariño
C
,
Larriba
MJ
,
García-Barberán
V
, et al
Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1
.
Oncogenesis
.
2018
Sep
;
7
(
9
):
76
.
[PubMed]
2157-9024
36.
Iacobuzio-Donahue
CA
,
Ashfaq
R
,
Maitra
A
,
Adsay
NV
,
Shen-Ong
GL
,
Berg
K
, et al
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies
.
Cancer Res
.
2003
Dec
;
63
(
24
):
8614
22
.
[PubMed]
0008-5472
37.
Wu
MH
,
Hong
TM
,
Cheng
HW
,
Pan
SH
,
Liang
YR
,
Hong
HC
, et al
Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons
.
Mol Cancer Res
.
2009
Mar
;
7
(
3
):
311
8
.
[PubMed]
1541-7786
38.
Croci
DO
,
Cerliani
JP
,
Dalotto-Moreno
T
,
Méndez-Huergo
SP
,
Mascanfroni
ID
,
Dergan-Dylon
S
, et al
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
.
Cell
.
2014
Feb
;
156
(
4
):
744
58
.
[PubMed]
0092-8674
39.
Croci
DO
,
Salatino
M
,
Rubinstein
N
,
Cerliani
JP
,
Cavallin
LE
,
Leung
HJ
, et al
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma
.
J Exp Med
.
2012
Oct
;
209
(
11
):
1985
2000
.
[PubMed]
0022-1007
40.
Dalotto-Moreno
T
,
Croci
DO
,
Cerliani
JP
,
Martinez-Allo
VC
,
Dergan-Dylon
S
,
Méndez-Huergo
SP
, et al
Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease
.
Cancer Res
.
2013
Feb
;
73
(
3
):
1107
17
.
[PubMed]
0008-5472
41.
Laderach
DJ
,
Gentilini
LD
,
Giribaldi
L
,
Delgado
VC
,
Nugnes
L
,
Croci
DO
, et al
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease
.
Cancer Res
.
2013
Jan
;
73
(
1
):
86
96
.
[PubMed]
0008-5472
42.
Orozco
CA
,
Martinez-Bosch
N
,
Guerrero
PE
,
Vinaixa
J
,
Dalotto-Moreno
T
,
Iglesias
M
, et al
Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk
.
Proc Natl Acad Sci USA
.
2018
Apr
;
115
(
16
):
E3769
78
.
[PubMed]
0027-8424
43.
Chan
J
. Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Jan 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT01782443
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.